Celebrating 25 years in optical imaging expertise with over 30,000 IVIS publications!

This month, we’re thrilled to celebrate a special milestone for our IVIS optical imaging technology. It’s been 25 years since the very first IVIS™ preclinical optical imaging system was launched, changing the way researchers study disease in animal models. Since then, IVIS has made it possible to monitor disease progression and treatment non-invasively over time, with incredible sensitivity through both bioluminescence and fluorescence detection.

Just as importantly, it has helped reduce the number of animals needed for research while strengthening the quality and statistical analysis. IVIS has now been cited in more than 30,000 peer-reviewed publications. These contributions have advanced drug discovery, expanded knowledge of disease, and reduced both the time and cost of moving toward clinical trials.

To celebrate this achievement, and to thank you, our community of researchers and users who made IVIS what it is today, we’re offering our biggest promotion ever across the entire IVIS range. Visit our website and find more information:

In Vivo Imaging | Revvity

Publication of the month

Chronically activated microglia in ALS gradually lose their immune functions and develop unconventional proteome.

In this paper, the Kriz Lab from Laval University uses TLR2-luc-GFP transgenic mice to study microglia activation and disease mechanisms. In this model, bioluminescence is induced when microglia are activated, and the signal can be captured using the IVIS preclinical optical imager.

Using imaging and proteomic analysis, the authors identified that chronically activated microglia have protein signatures associated with early and late-stage amyotrophic lateral sclerosis (ALS) pathology giving insight into previously unknown disease mechanisms.

Citation: Barreto-Núñez, et al. Glia. 2024, 72(7), 1319-1339

Read more: Chronically activated microglia in ALS gradually lose their immune functions and develop unconventional proteome - PubMed

Special Promotion

25th anniversary IVIS Special — 25% off the list price.*

Celebrate 25 years since the launch of the IVIS optical imaging system with a 25% discount from the list price of an IVIS instrument. See terms and conditions for details.

Contact us to learn more about this offer, finding your best solution and/or trading in current preclinical imaging technology — any brand, any modality considered!

View our promotion here
And contact here: salesau@revvity.com

Trade in discount

Unlock new research possibilities by upgrading your in vivo imaging capabilities. Whether you’re working with an older Revvity system or a competitor’s platform, our exclusive trade-in program offers you the perfect opportunity to advance your imaging capabilities while maximizing your investment.

Trade in any optical, microCT, or ultrasound imaging system and receive a discount toward a state-of-the-art Revvity in vivo imaging system. Our latest technologies deliver high sensitivity, resolution, and throughput to accelerate your discoveries.

Visit here: In Vivo Imaging Trade-In Program | Revvity